{"denoms":[{"counts":[{"groupId":"BG000","value":"14"}],"units":"Participants"}],"groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"BG000","title":"Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.31","value":"62.63"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}